StreetInsider.com News Articles

Form 8-K Celularity Inc For: Jun 26

Tue, 30 Jun 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26710653.html

Form 8-K Celularity Inc For: Jun 26

Tue, 30 Jun 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26710653.html

Form 8-K Celularity Inc For: Jun 19

Thu, 25 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260625/26693599.html

Form 8-K Celularity Inc For: Jun 19

Thu, 25 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260625/26693599.html

Form 4 Celularity Inc For: Jun 19 Filed by: Barach Philip Alan

Tue, 23 Jun 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260623/26677554.html

Form 4 Celularity Inc For: Jun 19 Filed by: Barach Philip Alan

Tue, 23 Jun 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260623/26677554.html

Form 4 Celularity Inc For: Jun 19 Filed by: Philip & Daniele Barach Family Trust

Tue, 23 Jun 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260623/26677557.html

Form 4 Celularity Inc For: Jun 19 Filed by: Philip & Daniele Barach Family Trust

Tue, 23 Jun 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260623/26677557.html

Form 4 Celularity Inc For: Jun 19 Filed by: Barach Daniele Wolf

Tue, 23 Jun 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20260623/26677547.html

Form 4 Celularity Inc For: Jun 19 Filed by: Barach Daniele Wolf

Tue, 23 Jun 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20260623/26677547.html

Form SCHEDULE 13D/A Celularity Inc Filed by: Philip & Daniele Barach Family Trust

Tue, 23 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26675404.html

Form SCHEDULE 13D/A Celularity Inc Filed by: Philip & Daniele Barach Family Trust

Tue, 23 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26675404.html

Form 8-K Celularity Inc For: Jun 09

Fri, 12 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26642078.html

Form 8-K Celularity Inc For: Jun 09

Fri, 12 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26642078.html

Celularity makes cell therapy available in Florida under new state law

Thu, 04 Jun 2026 08:03:07 -0400

Celularity Inc. (NASDAQ: CELU) announced the availability of cenplacel-L, a placental-derived cell therapy, for investigational use by licensed physicians in Florida under recently enacted state legislation. The company partnered with Fountain Life Management to provide the therapy through the new regulatory framework.

Florida Statutes § 458.3245 and § 459.0127, effective July 1, 2025, authorize licensed physicians to perform certain cell therapies not yet approved by the Food and Drug Administration, provided the treatments comply with sourcing, manufacturing, accreditation and patient consent requirements.

Cenplacel-L, also designated as PDA-001 or PDA-002 in clinical research, is manufactured at Celularity's FDA-registered, GMP-compliant facility. The therapy targets

Celularity makes cell therapy available in Florida under new state law

Thu, 04 Jun 2026 08:03:07 -0400

Cenplacel-L, also designated as PDA-001 or PDA-002 in clinical research, is manufactured at Celularity's FDA-registered, GMP-compliant facility. The therapy targets

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC (“Fountain Life”), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsible use of regenerative medicine.

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Form 8-K Celularity Inc For: May 29

Wed, 03 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26600374.html

Form 8-K Celularity Inc For: May 29

Wed, 03 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26600374.html

Celularity names Rick Gonzalez as chief commercial officer

Wed, 03 Jun 2026 16:15:17 -0400

Celularity Inc. (NASDAQ: CELU) announced the appointment of Rick Gonzalez as chief commercial officer, according to a shareholder letter from Chief Executive Officer Robert Hariri.

The cellular medicine company completed a transaction with NexGel Inc. to out-license commercial assets of its biomaterials business for up to $30 million. The deal eliminated approximately $13 million in recorded liabilities and allows Celularity to focus on placental-derived cellular therapy programs.

Celularity is concentrating resources on cenplacel-L, a placental-derived allogeneic cell therapy developed from postpartum placental tissue. The company reports physician interest in the therapy and expects revenue growth in 2026 driven by increasing physician participation

Celularity Releases CEO Letter to Shareholders

Wed, 03 Jun 2026 16:15:00 -0400

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.

Dear Fellow Shareholders,

I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context

Celularity Releases CEO Letter to Shareholders

Wed, 03 Jun 2026 16:15:00 -0400

Dear Fellow Shareholders,

I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context